MDCK II cells overexpressing MDR1 protein. A must assay for drug development.

MDR1 localitation
ReadyCell Communications Department
29 January 2021

The multidrug resistance protein 1, MDR1 is an efflux transporter that plays an important role in pharmacokinetic activity. This transmembranal transporter regulates the absorption, excretion, and distribution of xenobiotic compounds from the body. MDR1, also known as the P-gp receptor, is expressed in several tissues, such as the blood-brain barrier, liver, kidney cells and intestinal epithelium.

Since P-gp substrates include a broad range of clinically important and structurally diverse drugs, evaluation of P-glycoprotein (P-gp) affinity is mandatory for new molecular entities and is typically conducted during preclinical development stages. One of the recommended screening methods to study tissular permeability and drug-drug interactions is through cell-based in vitro kits. The in vitro technique is based on Madin Darby Canine Kidney (MDCK) cells transfected with the MDR1 gene (ABCB1), the gene encoding for the efflux protein P-gp. Obtaining MCDK II cells that overexpressess the MDR1 efflux protein in cell membrane.

According to ADME specialists, MDCK II – MDR1 in vitro kits are mainly indicated for,

  • Assessment of passive bidirectional transport to obtain pharmacokinetic knowledge for oral dose drug permeability in the intestinal tissue.
  • Blood-brain barrier permeability diffusion to predict central nervous system metabolism.
  • Evaluation of drug-efflux kinetics through the MDR1 receptor, which emulates P-gp expressing tissues’ mechanisms.
  • Drug-drug interaction studies that characterize pharmacological relevant MDR1 receptor affinity.

Main regulatory agencies require to evaluate MDR1 interactions due to their clinical importance in the absorption and disposition of drugs. Therefore, initial in vitro assessments are used to predict DDI potentials, aiding the development of an MDR1 transporter-based clinical drug interaction strategy.

PreadyPort-MDR1 ready-to-use kit is an innovative cell-based in vitro system for evaluating novel compounds’ metabolism, optimizing drug development, and preventing undesired side effects during later clinical stages.

ReadyCell develops high-performance in vitro kits specially designed for ADME-Tox assays. In case you need more detailed information, contact:

Related posts

Select the right well system for your research: A comprehensive guide.

Select the right well system for your research: A comprehensive guide.

In preclinical research, the choice of the appropriate well system format – whether it’s a transwell, non-transwell, or individual transwell – can significantly impact the outcome of experiments. Selecting the correct plate is crucial to working with permeability, toxicity, drug screening, or other assays.

Presenting the last advances in transporters in Germany

Presenting the last advances in transporters in Germany

On May 15-17, the 22nd Barrier- and Transporter- days took place in Germany. At the event, Jonatan Cucala, R&D researcher at ReadyCell, presented a poster entitled “PreadyTake, an in vitro ready-to-use cell-based model to evaluate potential drug-transporter interactions.”